Cryofocus Medtech – HK$210 Million IPO
Hong Kong – December 30, 2022 – Cooley advised the joint sponsors and underwriters of Cryofocus Medtech’s HK$210 million ($27 million) initial public offering of 11,110,000 H Shares on the Hong Kong Stock Exchange. Partners Michael Yu, Yiming Liu and Will Cai led the Cooley team.
Citigroup and Huatai Financial served as the joint sponsors and joint representatives for the global offering, with Citigroup, Huatai Financial, CMB International and ABCI Capital serving as joint global coordinators. Citigroup, Huatai Financial, CMB International, ABCI Securities, BOCOM International, Futu Securities, Tiger Brokers and Silverbricks Securities acted as the international and Hong Kong underwriters for the global offering.
Cryofocus is a medical device company in China with a focus on minimally invasive interventional cryotherapy. Since its inception in 2013, the company has developed a comprehensive product portfolio mainly focusing on two therapeutic areas: vascular interventional therapy and natural orifice transluminal endoscopic surgery.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,500 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
